Cargando…
Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients
BACKGROUND: Quality of life (QoL) data for patients with inflammatory bowel disease switched from the reference infliximab to biosimilar CT-P13 is lacking. This study aims to demonstrate noninferiority for QoL and efficacy after switching. METHODS: OoL and clinical efficacy were measured prior to an...
Autores principales: | Pierik, Marieke J, van der Meulen, Andrea E, Van der Linde, Klaas, Lutgens, Maurice, Kuijvenhoven, Johan P, Akol, Halil, Klompmaker, Ids J, Sikkens, Michelle S G, van Megen, Yvonne J B, Stoop, Corinne M, Bloemsaat-Minekus, Joanne P J, Dijkstra, Gerard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802295/ https://www.ncbi.nlm.nih.gov/pubmed/36777418 http://dx.doi.org/10.1093/crocol/otab001 |
Ejemplares similares
-
Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar
por: Meijboom, Rosanne W., et al.
Publicado: (2023) -
Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020) -
Biosimilar infliximab use in paediatric IBD
por: Richmond, Lisa, et al.
Publicado: (2018) -
Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019) -
PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)